Survival and multiplication of Burkholderia cepacia within respiratory epithelial cells

Clinical Microbiology and Infection

Volumn 4, Issue 8, 1998, Pages 450-459

  Tipper, Joanne L ^a   Ingham, Eileen ^a   Cove, Jonathan H ^a   Todd, Neil J ^b   Kerr, Kevin G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Burkholderia cepacia; Immunofluorescence; Invasion; Multiplication; Pseudomonas aeruginosa; Respiratory epithelial cells

Indexed keywords

CEFTAZIDIME; GENTAMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BURKHOLDERIA CEPACIA; CELL CULTURE; CONTROLLED STUDY; EPITHELIUM CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MONOLAYER CULTURE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; STRAIN DIFFERENCE;

EID: 0031660308     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00394.x     Document Type: Article

References (43)

1. Burkholder WH. Sour skin, a bacterial rot of onion bulbs. Phytopathology 1950; 40: 115-17.
2. Rosenstein BJ, Hall DE. Pneumonia and septicaemia due to Pseudomonas cepacia in a patient with cystic fibrosis. Johns Hopkins Med J 1980, 147: 188-9.
3. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia infection in cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985; 107: 382-7.
4. Tablan OC, Martone WJ, Doershuk CF et al. Colonisation of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcome. Chest 1987; 91: 527-32.
5. Friend PF. Pulmonary infection in cystic fibrosis. J Infect 1986; 13: 55-72.
6. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35-51.
7. Govan JRW, Glass S. The microbiology and therapy of cystic fibrosis lung infections. Microbiol Rev 1990; 1: 19-28.
8. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992; 48: 913-30.
9. Hoiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990; 45: 881-4.
10. Thomassen MJ, Demko CA, Khnger JD, Stern RC. Pseudomanas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis 1985; 131: 791-6.
11. Burns JL, Wadsworth CD, Chi E, Jonas M. Invasion of respiratory epithelium by Pseudomonas cepacia [abstract B-225]. In. Program and abstracts of the 92nd meeting of the American Society for Microbiology. Washington, DC: ASM, 1992; 63.
12. Burns JL, Jonas M, Chi EY, Clark DK, Berger A, Griffith A. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun 1996; 64: 4054-9.
13. Govan JRW, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
14. + Pseudomonas (Burkholderia) cepacia causing CF center epidemics in North America and Britain. Nature Med 1995; 1: 661-5.
15. van Putten JPM, Weel JFL, Grassmé HUC. Measurements of invasion by antibody labelling and electron microscopy. Methods Enzymol 1994; 236: 420-37.
16. Appleyard RK. Segregation of new lysogenic types during growth of a doubly lysogenic strain derived from Eschenchia coli K12. Genetics 1954; 39: 440-52.
17. Elsinghorst EA. Measurement of invasion by gentamicin resistance. Methods Enzymol 1994; 236: 405-20.
18. Kathariou S, Pine L, George V, Carolone GM, Holloway BP. Nonhemolytic Listeria monocytogenes mutants that are also non-invasive for mammalian cells in culture: evidence for co-ordinate regulation of virulence. Infect Immun 1990; 58: 3988-95.
19. Sokal RR, Rohlf FJ. Biometry, 2nd edn. New York: W. H. Freeman & Co., 1981.
20. Walters S, Smith EG. Pseudomonas cepacia in cystic fibrosis: transmissibility and implications. Lancet 1993; 342: 3-4.
21. Saiman L, Cacalano G, Prince A. Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa. Infect Immun 1990; 58: 2578-84.
22. Snell GI, de Hoyos, A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103: 466-71.
23. O'Neil KM, Herman JH, Modlin JF, Moxon ER, Winklestein JA. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J Pediatr 1986; 108: 940-2.
24. Pujol M, Corbella X, Carratala J, Gudiol F. Community acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis 1992; 15: 887-8.
25. Nelson JW, Butler SL, Krieg D, Govan JRW. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 1994; 8. 89-98.
26. McKevitt AI, Woods DE. Characterisation of Pseudomonas cepacia isolates from patients with cystic fibrosis J Clin Microbiol 1984; 19: 291-3.
27. Lonon MK, Woods DE, Straus DC. Production of lipase by clinical isolates of Pseudomonas cepacia. J Clin Microbiol 1988; 26: 976-84.
28. McKevitt AI, Babaksouzian S, Klinger JD, Woods DE. Purification and characterisation of an extracellular protease from Pseudomonas cepacia. Infect Immun 1989; 57: 771-8.
29. Straus DC, Woods DE, Lonon MK, Garner CW. The importance of extracellular antigens in Pseudomonas cepacia infections. J Med Microbiol 1988; 26: 269-80.
30. Straus DC, Lonon MK, Woods DE, Garner CW. Production of an extracellular toxic complex by various strains of Pseudomonas cepacia. J Med Microbiol 1989; 30: 17-22.
31. Sokol P. Production and utilisation of pychelin by clinical isolates of Pseudomonas cepacia. Infect Immun 1986; 23: 560-2.
32. Vasil ML, Krieg DP, Kuhns JS, et al. Molecular analysis of haemolytic and phospholipase C activities of Pseudomonas cepacia. Infect Immun 1990; 58: 4929-9.
33. Kuehn M, Lent K, Haas J, Hagenzieker J, Cervin M, Smith AL. Fimbriation of Pseudomonas cepacia. Infect Immun 1992; 60: 2002-7.
34. Sajjan US, Forstner JF. Role of a 22-kilodalton pilin protein in binding of Pseudomonas cepacia to buccal epithelial cells. Infect Immun 1993; 61: 3157-63.
35. Goldstein R, Sun L, Jiang R-Z, Sajjan U, Forstner JF, Campanelli C. Structurally variant classes of pilus appendage fibres coexpressed from Burkholderia (Pseudomonas) cepacia. J Bacteriol 1995; 177: 1039-52.
36. Sajjan US, Sun L, Goldstein R, Forstner JF. Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of cblA major subunit pilin gene and novel morphology of the assembled appendage fibres. J Bacteriol 1995; 177: 1030-8.
37. Burns JL. Characterisation of invasion of epithelial cells by P. cepacia. Pediatr Pulmonol 1992; Suppl 8: 201.
38. Ohya S, Xiong H, Tanabe Y, Arkawa M, Mitsuyama M. Killing mechanism of Listeria monocytogenes in activated macrophages as determined by an improved assay system. J Med Microbiol 1998; 47: 211-15.
39. Chi E, Mehl T, Nunn D, Lory S. Interaction of Pseudomonas aeruginosa with A549 pneumocyte cells. Infect Immun 1991; 59: 822-8.
40. Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis 1992; 15: 654-67.
41. Butler SL, Nelson JW, Poxton IR, Govan JRW. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol Med Microbiol 1994; 8: 285-92.
42. Gessner AR, Mortensen JE. Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Med Microbiol 1990; 33: 115-20.
43. Pruksachartvuthi S, Aswapokee N, Thankerngpol K. Survival of Pseudomonas pseudomaller in human phagocytes. J Med Microbiol 1990, 31: 109-14.